Jared Gollob - Mar 3, 2025 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Medical Officer
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol: KYMR
Transactions as of: Mar 3, 2025
Transactions value $: -$174,786
Form type: 4
Date filed: 3/3/2025, 06:30 PM
Previous filing: Jul 16, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Award	$0	+30K	+31.33%	$0.00	126K	Mar 3, 2025	Direct	F1
transaction	KYMR	Common Stock	Sale	-$142K	-4.7K	-3.73%	$30.33	121K	Mar 3, 2025	Direct	F2, F3
transaction	KYMR	Common Stock	Sale	-$32.4K	-1.05K	-0.86%	$31.00	120K	Mar 3, 2025	Direct	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Award	$0	+60K		$0.00	60K	Mar 3, 2025	Common Stock	60K	$30.17	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.
F2	Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.